You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

417 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT
ODB Limited Use
    lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria
ODB - General Benefit
    dexamethasone
Dec 2023
Drug
Other Name(s): Lynparza®
Jan 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Drug
Other Name(s): Padcev®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Guidelines and Advice
Oct 2023
Drug
Other Name(s): Camptosar®
Apr 2023
Drug
Other Name(s): Gemzar®
Dec 2023
Drug
Other Name(s): Columvi®
Jan 2025
Drug
Other Name(s): Epkinly™
Jan 2025
Drug
Other Name(s): Tecvayli®
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025

Pages